Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01811121 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS(RESECT) | completed | Phase 3 | 170 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03149575 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM(STAR-3) | terminated | Phase 3 | 2 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 4, 2025 |
| clinicaltrials |
| NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma(MIRAGE) | completed | Phase 3 | 749 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Jul 1, 2025 | clinicaltrials |
| NCT07004075 | FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration | not yet recruiting | Phase 3 | 102 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05439278 | Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma | recruiting | Phase 3 | 178 | Severance HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06750458 | Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients | not yet recruiting | Phase 3 | 75 | Tanta UniversityOTHER | 0 | Apr 22, 2025 | clinicaltrials |
| NCT03632135 | Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma(CSCRGBM) | completed | Phase 3 | 78 | Cordgenics, LLCINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02017717 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients(CheckMate 143) | completed | Phase 3 | 529 | Bristol-Myers SquibbINDUSTRY | 12 | Apr 4, 2025 | clinicaltrials |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | active not recruiting | Phase 3 | 331 | Institut de Recherches Internationales ServierOTHER | 11 | Apr 3, 2025 | clinicaltrials |
| NCT06749925 | Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma | not yet recruiting | Phase 3 | 186 | University of Sao Paulo General HospitalOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | active not recruiting | Phase 3 | 136 | Ascletis Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05512403 | Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics(KING) | recruiting | Phase 3 | 88 | Central Hospital, Nancy, FranceOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06477939 | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients(THREE-GLEES) | not yet recruiting | Phase 3 | 554 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | completed | Phase 3 | 260 | Denovo Biopharma LLCINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | suspended | Phase 3 | 234 | Precision Life Sciences GroupINDUSTRY | 3 | Apr 3, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06330337 | Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma | recruiting | Phase 3 | 58 | The Third Affiliated hospital of Zhejiang Chinese Medical UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT01502280 | Fluorescence-guided Surgery for Low- and High-grade Gliomas(BALANCE) | completed | Phase 3 | 127 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04532229 | Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | unknown | Phase 3 | 48 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05718466 | Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | completed | Phase 3 | 35 | Henry Ford Health SystemOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT02879682 | nTMS for Motor Mapping of Rolandic Lesions(Motorstim) | completed | Phase 2 / Phase 3 | 330 | Technical University of MunichOTHER | 3 | Jun 1, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT03534050 | Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy | unknown | Phase 2 / Phase 3 | 80 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)(FLEGME) | completed | Phase 3 | 51 | Rennes University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05600491 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | unknown | Phase 3 | 78 | Sun Yat-sen UniversityOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT03243461 | International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)(HIT-HGG-2013) | unknown | Phase 3 | 167 | University of GöttingenOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT00045968 | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer(GBM) | unknown | Phase 3 | 348 | Northwest BiotherapeuticsINDUSTRY | 4 | May 18, 2022 | clinicaltrials |
| NCT03763422 | Trial in Low Grade Glioma Patients: Wait or Treat(IWOT) | terminated | Phase 3 | 19 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Feb 1, 2022 | clinicaltrials |
| NCT02796261 | Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients(STELLAR) | unknown | Phase 3 | 343 | Orbus Therapeutics, Inc.INDUSTRY | 8 | Jan 21, 2022 | clinicaltrials |
| NCT02892708 | Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over(CSA) | completed | Phase 3 | 107 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT01479686 | iMRI Guided Resection in Cerebral Glioma Surgery | completed | Phase 3 | 321 | Huashan HospitalOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects(INTACT) | terminated | Phase 3 | 19 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 22, 2021 | clinicaltrials |
| NCT03008148 | Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | unknown | Phase 2 / Phase 3 | 288 | Johnpro Biotech, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT03025893 | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme(STELLAR) | unknown | Phase 2 / Phase 3 | 100 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03419403 | UNITE Study: Understanding New Interventions With GBM ThErapy | terminated | Phase 3 | 40 | AbbVieINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT04829097 | Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma | unknown | Phase 3 | 80 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02678975 | Disulfiram in Recurrent Glioblastoma | completed | Phase 2 / Phase 3 | 88 | Sahlgrenska University HospitalOTHER | 2 | Mar 18, 2021 | clinicaltrials |
| NCT01290939 | Bevacizumab and Lomustine for Recurrent GBM | completed | Phase 3 | 592 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04536649 | Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma. | unknown | Phase 3 | 369 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01649830 | Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma | unknown | Phase 3 | 290 | Sun Yat-sen UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04316039 | Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery | recruiting | Phase 2 / Phase 3 | 250 | West China HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT04277221 | ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) | unknown | Phase 3 | 118 | Safe Save Medical Cell Sciences & Technology Co.,Ltd.INDUSTRY | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT03722355 | Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma | completed | Phase 3 | 712 | Radiation Therapy Oncology GroupNETWORK | 0 | Nov 12, 2019 | clinicaltrials |
| NCT00295815 | Enzastaurin Versus Lomustine in Glioblastoma | completed | Phase 3 | 397 | Eli Lilly and CompanyINDUSTRY | 14 | Sep 12, 2019 | clinicaltrials |
| NCT00884741 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 3 | 637 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Sep 15, 2025source: clinicaltrials